Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is well-positioned as a clinical-stage biopharmaceutical company with a diverse pipeline of selective oral immunology therapies targeting a range of chronic inflammatory and autoimmune diseases. The company's products, including IMU-838, IMU-935, and IMU-856, show potential for addressing significant unmet needs in diseases such as ulcerative colitis and celiac disease. With the company operating in a single, focused life sciences segment and notable partnerships with global healthcare companies, Immunic's stock offers strong potential for long-term growth. At the same time, investors should carefully monitor clinical trial results and regulatory developments to assess the success and potential risks of Immunic's pipeline.

Bears say

Immunic is facing a number of challenges in advancing its pipeline, including potential technical pressure surrounding its recent reverse stock split, the need for significant follow-on financing, and the inherent risks of clinical trials and regulatory processes. Furthermore, the company's focus on targeting neurodegeneration may limit its market potential compared to therapies that primarily target inflammation and relapses. Despite its recent oversubscribed private placement, Immunic's fundamentals and financials may not support its ambitious commercial plans, posing a significant risk for investors.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.